Bashir Timol is Director, Chief Business Officer of the Company. Mr. Timol has been a Director since Nemaura Medical Inc. was organized on December 24, 2013. He has been a director of Dermal Diagnostics Limited from October 30, 2013. On April 9, 2018 Mr Timol was appointed to the role of Chief Business Officer. Mr. Timol possesses over 10 years’ experience in food and beverage, franchise, and logistic operations. His experience includes constructing sales contracts and having the responsibility for overseeing the key managers in the operation of a large scale retail food chain. He has experience as an entrepreneur investing in and operating a number of retail food chains in the UK, including DIXY Chicken and Costa Coffee. Prior to joining Nemaura Mr. Timol has been employed as a director at SABT 1 Ltd. since March of 2009 and One-E Group since January of 2007. Mr. Timol holds a bachelor degree in Economics from the University of Central Lancashire, UK.
Bashir Timol is 44, he's been the Director und Chief Business Officer of Nemaura Medical Inc since 2018. There are 6 older and 1 younger executives at Nemaura Medical Inc. The oldest executive at Nemaura Medical Inc is Thomas Moore, 55, who is the Independent Director.
Bashir's mailing address filed with the SEC is C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN, NY, 10019.
Over the last 7 years, insiders at Nemaura Medical Inc have traded over $0 worth of Nemaura Medical Inc stock and bought 100,000 units worth $14,000 . The most active insiders traders include Arash Ghadar Ghadr. On average, Nemaura Medical Inc executives and independent directors trade stock every 0 days with the average trade being worth of $3,000. The most recent stock trade was executed by Arash Ghadar Ghadr on 5 January 2024, trading 100,000 units of NMRD stock currently worth $14,000.
nemaura medical inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. the company provides sugarbeat, a non-invasive continuous glucose monitoring device for use by persons with type i and type ii diabetes, as well as for screening pre-diabetic patients. it has a license agreement with healthimation, llc, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for type 2 diabetes, prediabetes, and general wellness; the why wait app; and common law trademarks which incorporate the mark why wait or whywait and the use of licensed marks. nemaura medical inc. was founded in 2009 and is based in new york, new york.
Nemaura Medical Inc executives and other stock owners filed with the SEC include: